Data Providers · Flatiron Health
natural-history study comparing early-onset gastric/colorectal cancer prevalence in Japan vs. the US using EHR-derived RWD
The customer is anonymised in Flatiron Health’s own case study — not withheld by us.
Flatiron Health is a Roche-owned company supplying EHR-derived oncology real-world data, captured at the source through its own OncoEMR software.
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Source
Published by Flatiron Health on its own site — read the original case study on resources.flatiron.com ↗
More like this
Related use cases
- 01used Flatiron's Enhanced Data Mart for real-world/external-control analysis supporting Canadian HTA reimbursement approval of a BRAF V600E–targeted NSCLC treatment
- 02used Flatiron's Clinical Genomics Database (with Foundation Medicine) for a natural-history study of 743 KRAS G12C patients supporting Lumakras FDA approval
- 03used Flatiron's Spotlight database for benchmark/indirect-comparison analyses supporting the mobocertinib (Exkivity, EGFR Exon20ins) regulatory/HTA submission
- 04used de-identified Flatiron EHR data to study unmet need in mantle cell lymphoma post-cBTKi therapy, supporting FDA accelerated approval of pirtobrutinib
- 05used Flatiron real-world data to compare overall survival of niraparib maintenance therapy vs. active surveillance in recurrent ovarian cancer
- 06used EHR-derived RWD to identify low-LVEF metastatic breast cancer patients on Kadcyla (T-DM1), fulfilling a post-approval regulatory commitment and securing label updates in the US/EU/Canada